Xenetic Biosciences, Inc. is a biopharmaceutical company developing next generation biologic drugs and novel oncology therapeutics. Xenetic s proprietary drug technology platforms include PolyXen , designed to develop next generation biologic drugs by extending the efficacy, safety and half life of biologic drugs. Xenetic s lead product candidates include ErepoXen , a polysialylated form of erythropoietin for the treatment of anemia in pre dialysis patients with chronic kidney disease, and FDA orphan designated oncology therapeutics Virexxa and Oncohist for the treatment of progesterone receptor negative endometrial cancer and refractory acute myeloid leukemia. Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications. For more information, please visit the company s website at www.xeneticbio.com.
Quote | Xenetic Biosciences Inc. (NASDAQ:XBIO)
Last: | $4.01 |
---|---|
Change Percent: | -2.04% |
Open: | $3.82 |
Close: | $4.01 |
High: | $4.01 |
Low: | $3.82 |
Volume: | 2,664 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Xenetic Biosciences Inc. (NASDAQ:XBIO)
2024-05-22 17:20:43 ET More on Xenetic Biosciences Seeking Alpha’s Quant Rating on Xenetic Biosciences Historical earnings data for Xenetic Biosciences Financial information for Xenetic Biosciences Read the full article on Seeking Alpha For fur...
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...
Message Board Posts | Xenetic Biosciences Inc. (NASDAQ:XBIO)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $XBIO News Article - Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise wi | whytestocks | investorshangout | 05/04/2023 3:10:47 PM |
whats going on over here?????? nice moves | fireballka7 | investorshub | 01/31/2023 9:01:35 PM |
znewcar1: $XBIO 9% v147K hod.63 f15,166M ML.27 LL.24 followed the 9ema up to hod and a 5/8 fraction | znewcar1 | investorshangout | 01/30/2023 8:32:52 PM |
whytestocks: $XBIO News Article - Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th A | whytestocks | investorshangout | 09/07/2022 6:41:03 PM |
znewcar1: Hey J L, You said XBIO was a Buy Alert @ $2.8 how's about @ $1.3? | znewcar1 | investorshangout | 12/24/2021 6:09:26 AM |
News, Short Squeeze, Breakout and More Instantly...
Xenetic Biosciences Inc. Company Name:
XBIO Stock Symbol:
NASDAQ Market:
Xenetic Biosciences Inc. Website:
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the qu...
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...